Drug profile · INN
naphazoline hydrochloride
ALBALON
- US status
- approved
- Patents linked
- 8
- News articles
- 0
Quick answer
naphazoline hydrochloride (ALBALON) is an FDA-listed pharmaceutical active ingredient. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Related patents
Search patents →-
US 12156862
Medicaments for the treatment of vasoconstriction related diseases or disorders
granted -
US 9555037
Method of using vasoconstrictive agents during energy-based tissue therapy
granted -
US 9271985
Method of using vasoconstrictive agents during energy-based tissue therapy
granted -
US 8968234
Method of using vasoconstrictive agents during energy-based tissue therapy
granted -
US 8945108
Method of using vasoconstrictive agents during energy-based tissue therapy
granted -
US 8202242
Method of using vasoconstrictive agents during energy-based tissue therapy
granted -
US 7109245
Vasoconstrictor cannabinoid analogs
granted -
US 6365725
DNA coding for a human vasoconstrictive peptide and use thereof
expired
Frequently asked questions
What is naphazoline hydrochloride?
naphazoline hydrochloride (ALBALON) is an FDA-listed pharmaceutical active ingredient. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for naphazoline hydrochloride?
ALBALON is a marketed brand name for naphazoline hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of naphazoline hydrochloride?
naphazoline hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.